| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74971605P | 2005-12-12 | 2005-12-12 |
| Publication Number | Publication Date |
|---|---|
| DOP2006000277Atrue DOP2006000277A (en) | 2007-08-31 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2006000277ADOP2006000277A (en) | 2005-12-12 | 2006-12-08 | ANTI MN ANTIBODIES AND METHODS FOR USE |
| Country | Link |
|---|---|
| US (2) | US8168758B2 (en) |
| EP (2) | EP2476706A3 (en) |
| JP (2) | JP2009519341A (en) |
| KR (1) | KR101551878B1 (en) |
| CN (2) | CN102585001B (en) |
| AR (1) | AR058325A1 (en) |
| AU (1) | AU2006326476A1 (en) |
| BR (1) | BRPI0619606A2 (en) |
| CA (1) | CA2633038A1 (en) |
| CR (1) | CR10068A (en) |
| DO (1) | DOP2006000277A (en) |
| EC (1) | ECSP088529A (en) |
| ES (1) | ES2428373T3 (en) |
| GT (1) | GT200800098A (en) |
| HN (1) | HN2008000878A (en) |
| IL (1) | IL192129A0 (en) |
| MA (1) | MA30684B1 (en) |
| MX (1) | MX2008007502A (en) |
| NZ (1) | NZ569698A (en) |
| PE (2) | PE20071055A1 (en) |
| RU (2) | RU2427590C2 (en) |
| SG (1) | SG170793A1 (en) |
| TN (1) | TNSN08255A1 (en) |
| TW (2) | TWI392686B (en) |
| UY (1) | UY30006A1 (en) |
| WO (1) | WO2007070538A2 (en) |
| ZA (1) | ZA200805741B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2802205C (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| EP3858387A1 (en) | 2003-11-06 | 2021-08-04 | Seagen Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| RU2557319C2 (en) | 2007-07-16 | 2015-07-20 | Дженентек, Инк. | HUMANISED ANTIBODIES AGAINST CD79b AND IMMUNOCONJUGATES AND METHODS OF APPLICATION |
| DK2176296T3 (en) | 2007-07-16 | 2012-05-21 | Genentech Inc | Anti-CD79B antibodies and immune conjugates and methods of use. |
| TWI489993B (en) | 2007-10-12 | 2015-07-01 | Novartis Ag | Compositions and methods of use for antibodies against sclerostin |
| MX351557B (en) | 2008-01-31 | 2017-10-19 | Genentech Inc | ANTI-CD79B ANTIBODIES and IMMUNOCONJUGATES and METHODS OF USE. |
| KR101711672B1 (en) | 2008-09-26 | 2017-03-03 | 온코메드 파마슈티칼스, 인크. | Frizzled Binding Agents and Uses Thereof |
| US20140024050A1 (en)* | 2009-03-10 | 2014-01-23 | Abbott Laboratories | Antibodies which detect pivkaii and methods of use thereof |
| PL2406284T3 (en) | 2009-03-10 | 2017-09-29 | Biogen Ma Inc. | Anti-bcma antibodies |
| ES2617281T3 (en) | 2009-10-28 | 2017-06-16 | Janssen Biotech, Inc. | Anti-glp-1r antibodies and their uses |
| TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
| JP2011206049A (en)* | 2010-03-08 | 2011-10-20 | Sumio Sugano | Necrosis marker and use thereof |
| KR20130043102A (en) | 2010-04-01 | 2013-04-29 | 온코메드 파마슈티칼스, 인크. | Frizzled-binding agents and uses thereof |
| TWI582112B (en) | 2011-04-21 | 2017-05-11 | 西雅圖遺傳學公司 | New binder-drug conjugates (adcs) and use thereof |
| KR20140114826A (en) | 2011-12-14 | 2014-09-29 | 시애틀 지네틱스, 인크. | Fgfr antibody drug conjugates (adcs) and the use thereof |
| AU2012356170B2 (en) | 2011-12-21 | 2016-06-16 | Novartis Ag | Compositions and methods for antibodies targeting Factor P |
| JP2016510411A (en) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Methods and monitoring of treatment with WNT pathway inhibitors |
| US8975290B2 (en)* | 2013-03-01 | 2015-03-10 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
| US20160208016A1 (en)* | 2013-08-29 | 2016-07-21 | University Of Copenhagen | Anti-ADAM12 antibodies for the treatment of cancer |
| PT3086814T (en) | 2013-12-23 | 2020-09-04 | Bayer Pharma AG | Antibody drug conjugates (adcs) with kinesin spindel protein (ksp) |
| RS60349B8 (en) | 2014-09-23 | 2022-10-31 | Hoffmann La Roche | Method of using anti-cd79b immunoconjugates |
| EP3233127A1 (en) | 2014-12-15 | 2017-10-25 | Bayer Pharma Aktiengesellschaft | Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies |
| SG11201710639YA (en) | 2015-06-22 | 2018-01-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| EP3313522A1 (en) | 2015-06-23 | 2018-05-02 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies |
| CA2990394A1 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| KR20180123047A (en) | 2016-03-24 | 2018-11-14 | 바이엘 파마 악티엔게젤샤프트 | Prodrugs of cytotoxic activators with enzymatically cleavable groups |
| CN109310781B (en) | 2016-06-15 | 2024-06-18 | 拜耳制药股份公司 | Specific antibody-drug-conjugates (ADC) having a KSP inhibitor and an anti-CD 123-antibody |
| IL310558A (en) | 2016-12-21 | 2024-03-01 | Bayer Pharma AG | Antibody drug conjugates (adcs) having enzymatically cleavable groups |
| WO2018114804A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
| KR20190099250A (en) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | Prodrugs of Cytotoxic Active Agents with Enzymatically Cleavable Groups |
| EP3746079A1 (en) | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| US20210275686A1 (en) | 2018-06-18 | 2021-09-09 | Bayer Aktiengesellschaft | Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile |
| MX2021005686A (en) | 2018-11-14 | 2021-07-07 | Bayer Ag | Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer. |
| US12221479B2 (en) | 2018-12-19 | 2025-02-11 | Bayer Aktiengesellschaft | Pharmaceutical combination of anti CEACAM6 and TIM3 antibodies |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| EP4087657A1 (en) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| EP4129333A4 (en)* | 2020-03-27 | 2024-06-12 | PhotoQ3 Inc. | PHARMACEUTICAL MEDICINAL PRODUCT FOR THE DESTROYING OF TUMOR CELLS |
| CN116635064A (en) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | A chimeric antigen receptor system with adaptive receptor specificity |
| CN113281513B (en)* | 2021-05-17 | 2024-05-28 | 上海执诚生物科技有限公司 | MMP-3 kit and preparation method and application thereof |
| TW202434305A (en) | 2022-11-17 | 2024-09-01 | 德商溫瑟克斯製藥公司 | Antibody-drug conjugates cleavable in a tumor microenvironment |
| CN116444653B (en)* | 2023-03-09 | 2024-03-15 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | Preparation and application of blocking African swine fever virus monoclonal antibody hybridoma cell strain |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| CN118063606B (en)* | 2024-04-24 | 2024-07-05 | 江西赛基生物技术有限公司 | An anti-THSD7A monoclonal antibody and its preparation method and application |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US564830A (en) | 1896-07-28 | Sprocket-chain and wheel | ||
| US1399790A (en) | 1919-09-25 | 1921-12-13 | James J Phillips | Winding means for spring-motors |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| CH652145A5 (en) | 1982-01-22 | 1985-10-31 | Sandoz Ag | METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE. |
| US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4454106A (en) | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US4745181A (en) | 1986-10-06 | 1988-05-17 | Ciba Corning Diagnostics Corp. | Polysubstituted aryl acridinium esters |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| ATE144793T1 (en) | 1989-06-29 | 1996-11-15 | Medarex Inc | BISPECIFIC REAGENTS FOR AIDS THERAPY |
| DK0463151T3 (en) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Generation of xenogenic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2093022C (en) | 1990-10-05 | 2005-02-22 | Michael W. Fanger | Targeted immunostimulation with bispecific reagents |
| EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
| US5773280A (en) | 1992-03-20 | 1998-06-30 | The Board Of Trustees Of The University Of Illinois | Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses |
| ES2093778T3 (en) | 1991-04-26 | 1997-01-01 | Surface Active Ltd | NEW ANTIBODIES AND METHODS FOR USE. |
| US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
| US5407653A (en) | 1991-06-26 | 1995-04-18 | Brigham And Women's Hospital | Evaluation of the multidrug resistance phenotype |
| ATE207080T1 (en) | 1991-11-25 | 2001-11-15 | Enzon Inc | MULTIVALENT ANTIGEN-BINDING PROTEINS |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE239506T1 (en) | 1992-03-05 | 2003-05-15 | Univ Texas | USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND/OR THERAPY OF VASCULARIZED TUMORS |
| US6297041B1 (en) | 1992-03-11 | 2001-10-02 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
| US5387676A (en)* | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
| US5981711A (en)* | 1992-03-11 | 1999-11-09 | Institute Of Virology, Slovak Academy Of Sciences | MN-specific antibodies and hybridomas |
| DE614989T1 (en) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Method for in vivo selection of ligand binding proteins. |
| US5395752A (en) | 1993-03-19 | 1995-03-07 | Ciba Corning Diagnostics Corp. | Long emission wavelength chemiluminescent compounds and their use in test assays |
| EP0787185A2 (en) | 1994-10-20 | 1997-08-06 | MorphoSys AG | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| JP4436457B2 (en) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | Protein / (poly) peptide library |
| US7264963B1 (en) | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
| HUP9904177A3 (en) | 1996-09-26 | 2001-10-29 | Chugai Pharmaceutical Co Ltd | Antibody against human parathormone related peptides |
| SE9700384D0 (en) | 1997-02-04 | 1997-02-04 | Biacore Ab | Analytical method and apparatus |
| ES2285769T3 (en) | 1997-05-15 | 2007-11-16 | Chugai Seiyaku Kabushiki Kaisha | REMEDY FOR CAQUEXY. |
| CA2297070A1 (en) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
| DK1030839T3 (en) | 1997-11-10 | 2004-05-03 | Searle & Co | Use of alkylated imino sugars to treat multidrug resistance |
| US6200814B1 (en) | 1998-01-20 | 2001-03-13 | Biacore Ab | Method and device for laminar flow on a sensing surface |
| US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| WO2001002588A2 (en) | 1999-07-02 | 2001-01-11 | Morphosys Ag | Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
| IL142025A0 (en) | 1999-07-20 | 2002-03-10 | Morphosys Ag | Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds |
| IT1307309B1 (en) | 1999-12-30 | 2001-10-30 | Enea Ente Nuove Tec | STABILIZING PEPTIDES, POLYPEPTIDES AND ANTIBODIES THAT INCLUDE THEM. |
| AU2002238537B8 (en)* | 2001-02-07 | 2006-08-24 | Wilex Ag | Hybridoma cell line G250 and its use for producing monoclonal antibodies |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| AR036833A1 (en)* | 2001-10-18 | 2004-10-06 | Bayer Corp | HUMAN ANTIBODIES THAT JOIN MN AND HAVE NEUTRALIZING ACTIVITY OF CELLULAR ADHESION. |
| AU2002351208A1 (en)* | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen |
| AU2002359130A1 (en) | 2001-12-21 | 2003-07-15 | Biacore Ab | Immobilization of binding agents |
| AR038568A1 (en) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | ANTI-A BETA ANTIBODIES AND ITS USE |
| WO2003100029A2 (en)* | 2002-02-21 | 2003-12-04 | Bayer Healthcare | Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| JP2005536220A (en)* | 2002-08-23 | 2005-12-02 | カイロン コーポレイション | Therapeutic compositions and methods for cancer characterized by the expression of tumor associated antigen MN / CAIX |
| JP2004170195A (en) | 2002-11-19 | 2004-06-17 | Reverse Proteomics Research Institute Co Ltd | Protein immobilization method |
| CN104119439A (en)* | 2003-06-27 | 2014-10-29 | 艾默根佛蒙特有限公司 | Antibodies directed to deletion mutants of epidermal growth factor receptor and uses thereof |
| CN1281753C (en)* | 2003-12-08 | 2006-10-25 | 陈志南 | Monoclonal antibody CAb-1 heavy and light chain variable region gene of human carcinoma of large intestine, and its uses |
| SE0303319D0 (en) | 2003-12-10 | 2003-12-10 | Biacore Ab | Sample flow positioning method and analytical system using the method |
| EP1766398B1 (en) | 2004-06-24 | 2011-01-05 | GE Healthcare Bio-Sciences AB | Method for detecting molecular surface interactions |
| SE0402476D0 (en) | 2004-10-13 | 2004-10-13 | Biacore Ab | Preparation and use of a reactive solid support surface |
| Publication | Publication Date | Title |
|---|---|---|
| DOP2006000277A (en) | ANTI MN ANTIBODIES AND METHODS FOR USE | |
| CU20120095A7 (en) | PCSK9 ANTAGONISTS | |
| CY1120904T1 (en) | IMPROVED TESTOSTERONE GEL AND METHOD OF USE IN THE TREATMENT OF HYPODONGISM | |
| CY1118760T1 (en) | MODIFIED ANTIBODIES AGAINST IL-23 | |
| EP1844077A4 (en) | DR5 ANTIBODIES AND USES THEREOF | |
| CY1117124T1 (en) | HUMANIZED ANTI-β7 ANTAGONISTS AND THEIR USES | |
| PH12013500277A1 (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| MY166776A (en) | Humanised anti-ctla4 antibodies | |
| MA32982B1 (en) | Binding proteins to human cgrp receptors | |
| CY1111622T1 (en) | ANTI-CMET HUMANIZED COMPETITORS | |
| NI200800032A (en) | REDUCTION OF CELL B USING SPECIFIC JOINT MOLECULES CD37 AND CD20 | |
| AR057807A1 (en) | ANTI-CD3 ANTIBODY FORMULATIONS | |
| TR200906131T1 (en) | Activin-actrIIa antagonists and treatment of breast cancer | |
| PH12014500903A1 (en) | Bispecific immunobinders directed against tnf and il-17 | |
| EA200900040A1 (en) | ANTIBODY MOLECULES THAT ASSOCIATE WITH HUMAN IL-17 | |
| NO20083397L (en) | Anti-EphB4 antibodies and methods for their use | |
| WO2009118662A3 (en) | Methods and compositions for treating bone loss | |
| UA109633C2 (en) | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
| ECSP13012673A (en) | METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY FOR NEURAL DISEASE | |
| WO2007035092A3 (en) | Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates | |
| EA201201324A1 (en) | PREVENTION OF COLORECTAL AND GASTROINTESTINAL CANCER | |
| NO20091181L (en) | Anti-C5AR antibodies with enhanced properties | |
| WO2011053565A3 (en) | Compositions and methods for detecting a tauopathy | |
| NO20083593L (en) | Anti-EphrinB2 antibodies and methods for their use | |
| EA201290630A1 (en) | TREATMENT OF DISORDERS OF EXCHANGE OF SUBSTANCES |